Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jazz Pharmaceuticals PLC

JAZZ
Current price
121.65 USD -2.62 USD (-2.11%)
Last closed 124.27 USD
ISIN USG508711052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 472 793 088 USD
Yield for 12 month +0.90 %
1Y
3Y
5Y
10Y
15Y
JAZZ
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

176.17 USD

P/E ratio

17.5085

Dividend Yield

Current Year

+3 834 204 000 USD

Last Year

+3 659 374 000 USD

Current Quarter

+1 054 969 000 USD

Last Quarter

+1 023 825 000 USD

Current Year

+2 790 343 000 USD

Last Year

+3 118 857 000 USD

Current Quarter

+943 358 000 USD

Last Quarter

+758 700 000 USD

Key Figures JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 518 480 000 USD
Operating Margin TTM 24.67 %
PE Ratio 17.5085
Return On Assets TTM 4.62 %
PEG Ratio 0.9598
Return On Equity TTM 12.09 %
Wall Street Target Price 176.17 USD
Revenue TTM 3 992 711 936 USD
Book Value 69.01 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 8.5 %
Dividend Yield
Gross Profit TTM 3 392 249 000 USD
Earnings per share 7.06 USD
Diluted Eps TTM 7.06 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 59.7 %
Profit Margin 11.6 %

Dividend Analytics JAZZ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 17.5085
Forward PE 6.7204
Enterprise Value Revenue 2.7694
Price Sales TTM 1.8716
Enterprise Value EBITDA 8.4622
Price Book MRQ 1.7917

Financials JAZZ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators JAZZ

For 52 weeks

99.06 USD 134.17 USD
50 Day MA 110.64 USD
Shares Short Prior Month 3 377 346
200 Day MA 112.91 USD
Short Ratio 5.52
Shares Short 3 491 132
Short Percent 7.48 %